Kidney International Publishes the ADA-KDIGO Consensus Report on Diabetes Management in CKDjbrown
The consensus report identifies and highlights shared recommendations from the 2022 American Diabetes Association (ADA) Standards of Medical Care in Diabetes and the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
Read the consensus report here.
Consensus statements were drafted when recommendations from each organization aligned and were supported by high-quality evidence from randomized clinical trials. Clear direction is provided on CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management to improve the clinical outcomes of people with diabetes and CKD.
Consensus statements provide specific guidance on the use of renin-angiotensin system inhibitors, metformin, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist.
The report recommends a holistic approach to care where pharmacotherapy proven to improve kidney and cardiovascular outcomes complements a healthy lifestyle.